Stay updated on Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-17T04:40:01.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11.
    Difference
    0.3%
    Check dated 2025-08-10T00:32:55.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-01T18:54:24.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.16.6 to v2.16.8 and added a section on HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-25T13:53:33.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-18T10:50:11.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-11T07:09:13.000Z thumbnail image

Stay in the know with updates to Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.